🇺🇸 rFVIIIFc in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 22 April 2025 – 22 April 2026
Total reports: 4

Most-reported reactions

Body Temperature Increased — 1 report (25%)
Constipation — 1 report (25%)
Haemophilic Arthropathy — 1 report (25%)
Viral Infection — 1 report (25%)

Source database →

Other Hematology approved in United States

Frequently asked questions

Is rFVIIIFc approved in United States?

rFVIIIFc does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for rFVIIIFc in United States?

Bioverativ Therapeutics Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.